- Home
- AEON vs SKYE Comparison
AEON vs SKYE Comparison
Compare AEON & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | SKYE |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.8M | 24.2M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | AEON | SKYE |
|---|---|---|
| Price | $0.89 | $0.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.20 | ★ $15.00 |
| AVG Volume (30 Days) | 69.5K | ★ 189.6K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.57 |
| 52 Week High | $1.45 | $5.75 |
Technical Indicators
Market Signals| Indicator | AEON | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 65.82 |
| Support Level | $0.87 | $0.68 |
| Resistance Level | $1.12 | $0.83 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 12.07 | 94.81 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.